Latest Commercial Execution News

CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.

Vinyl Group grew FY26 revenue by 31% and nearly halved its net loss, but auditors flagged a material uncertainty over the company’s ability to continue as a going concern. The ASX-listed media group is now relying on acquisition-led growth, higher margins and possible future funding to reach profitability.

Volt Resources has secured US$5.4 million in fully government-funded support for its US graphite refinery and customer application centre. The award is positive for project funding, but the company’s ASX securities remain suspended as it works with the exchange to satisfy reinstatement requirements.

Pacific Edge is positioning Cxbladder for a Medicare-led recovery, but the company remains loss-making with NZ$7.8 million in net cash after a difficult FY26. The investment case now turns on final US coverage, test volumes and whether the enlarged balance sheet can carry the business to scale.

Peppermint Innovation has shifted from building its Philippines payments platform to commercialising it, but the FY26 report shows the business remains loss-making, balance-sheet constrained and dependent on future funding. The company reported A$217,720 in revenue, a A$2.40 million net loss and negative net assets of A$578,233.

Adisyn Ltd reshuffles leadership with Kevin Crofton stepping up as Executive Chairman while Arye Kohavi moves to a Non-Executive Director role, signalling a strategic pivot to accelerate commercial execution in semiconductor technology.

EBR Systems has secured ISO 13485 certification for its new Santa Clara manufacturing site, paving the way for a 500% increase in WiSE System production pending FDA approval expected by year-end.

IMEXHS Limited reported a 12% rise in annual recurring revenue to $36.8 million in 1H FY26, powered by its AI-enabled radiology platform now live in a public hospital network. Underlying EBITDA surged 311% to $1.27 million despite ongoing sector liquidity challenges in Colombia.

Peppermint Innovation Limited posted a $2.4 million net loss for FY26 as it shifted from platform development to commercial execution in the Philippines, achieving key regulatory milestones and securing strategic investment.

Clever Culture Systems expanded its pharmaceutical customer base to eight in FY26, placing 11 APAS Independence instruments and completing its product offering with a contact plate module. Despite a $2.24 million net loss, the company expects meaningful sales growth in FY27 backed by a robust pipeline and disciplined financial management.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

Mach7 Technologies reported a 17.4% revenue drop to $27.9 million and a 44% increase in net loss to $8.9 million for FY26, driven by a strategic transition to a subscription model and cost base restructuring.